Is this news to anybody?

[kapakahi]

A new treatment for terminal head and neck cancer patients - combining two immunotherapy drugs, nivolumab and ipilimumab. The CheckMate 651 trial, funded by Bristol Myers Squibb - showed especially good results in tumors with high levels of a marker called PD-L1. I don't know that any of this could pertain to APC, but it seems there have been other trials combining these two monoclonal antibody medications in kidney, skin and colon cancers. Seems so simple that something like this has to have been tried with PC, but...maybe there have been other combinations?

theguardian.com/society/2021/oct/11/new-cancer-treatment-destroys-tumours-in-terminally-ill-finds-trial

[tango65]

This link has preliminary results of the checkmate 650 trial. It seems to me not very effective in APC and grade 3-4 side effects in about 50% of the patients.

pubmed.ncbi.nlm.nih.gov/329...

More recent data show most patients with APC do not respond to this treatment:

cancernetwork.com/view/nivo...

[kapakahi in reply to tango65]

good to know - thanks

[addicted2cycling in reply to tango65]

tango65 wrote --- " ... More recent data show most patients with APC do not respond to this treatment:

cancernetwork.com/view/nivo... "

from above ^^^ " ... Phase 2 data found that the combination of nivolumab plus ipilimumab demonstrated significant anti-tumor activity for patients with mCRPC... "

??? am I reading the mentioned quote wrong ???

[tango65 in reply to addicted2cycling]

Only 29% of tbe patients have some PSA response. My understsanding is that most of the patients 71% did not responded to the drugs.

[kapakahi in reply to tango65]

I guess I was asking if combinations of other MABs, either one of these with another MAB or two or more entirely different ones, have been tried - I would guess so, but don't know.

[tango65 in reply to kapakahi]

These drugs may have serious side effects,

I think these drugs should be used in cancers which have some genetic alterations which make them susceptible to the drugs, particularly, microsatellite instability-high (MSI-H) or a mismatch repair deficient (dMMR) and/or be PDL-1 positive.

These genetic defects have a low incidence in prostate cancer, so they are doing blind studies combining drugs and most patients do not respond, but about 30% respond.

I was offered one of these trials but I refused because they do not test the genome of the cancer (somatic genome) before accepting the patients.

[LeeLiam]

I believe Dr. Onik uses cryo on a tumor then injects the tumor with ipilimumab, pembrolizumab or nivolumab. He seems to have cured metastatic disease in many men. In a study with 19 metastatic men almost half had a complete response and another 1/4 had stable disease; cancerres.aacrjournals.org/...

I thought addicted2cycling had this treatment. a2c, care to comment?

[addicted2cycling in reply to LeeLiam]

LeeLiam wrote --- " ... I thought addicted2cycling had this treatment. a2c, care to comment? "

Yes with cryo + injection in GL10 back in 2015 BUT it was 1st use with degree of my PCa diagnosis AND HAS BEEN MODIFIED (improved) since.

BTW - NO side effects experienced.